Literature DB >> 16922643

Sildenafil: efficacy, safety, tolerability and mechanism of action in treating erectile dysfunction.

Sharron H Francis1, Jackie D Corbin.   

Abstract

Sildenafil citrate is marketed under the trademark name Viagra and is widely used to treat male erectile dysfunction; therapeutic uses of this medication for other diseases related to vascular dysfunction are emerging. When used as recommended, the drug has a strong clinical efficacy and safety profile in a broad spectrum of the male population. Its widespread use and effects of long-term exposure to the drug due to particular treatment regimens or inappropriate use mandate an ongoing update of its molecular mechanism, pharmacological profile and associated safety issues. This review focuses on biochemical and pharmacological features of sildenafil, the active component in Viagra, interaction of sildenafil with phosphodiesterase 5, pharmacokinetic parameters, action in smooth muscle, side effects, safety profile and prospects for other uses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16922643     DOI: 10.1517/17425255.1.2.283

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  13 in total

1.  Phosphodiesterase inhibitors in vascular ischemia: A case report and review of their use in ischemic conditions.

Authors:  Wendy Ky Ng; Yishai Rosenblatt; Gerald B Brock; David B O'Gorman; Bing Siang Gan
Journal:  Can J Plast Surg       Date:  2010

Review 2.  International Union of Basic and Clinical Pharmacology. CI. Structures and Small Molecule Modulators of Mammalian Adenylyl Cyclases.

Authors:  Carmen W Dessauer; Val J Watts; Rennolds S Ostrom; Marco Conti; Stefan Dove; Roland Seifert
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

3.  Post-stroke Sexual Dysfunction in Men: Epidemiology, Diagnostic Work-up, and Treatment.

Authors:  Rocco Salvatore Calabrò
Journal:  Innov Clin Neurosci       Date:  2022 Jul-Sep

Review 4.  [The basics of phosphodiesterase type 5 (PDE5) inhibition in urology].

Authors:  A J Becker; S Uckert; C G Stief
Journal:  Urologe A       Date:  2008-12       Impact factor: 0.639

5.  Contractile agonists attenuate cGMP levels by stimulating phosphorylation of cGMP-specific PDE5; an effect mediated by RhoA/PKC-dependent inhibition of protein phosphatase 1.

Authors:  K S Murthy
Journal:  Br J Pharmacol       Date:  2008-01-21       Impact factor: 8.739

Review 6.  Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension.

Authors:  Gautam V Ramani; Myung H Park
Journal:  Drug Des Devel Ther       Date:  2010-05-25       Impact factor: 4.162

7.  cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium.

Authors:  Fabrice Vandeput; Judith Krall; Ramzi Ockaili; Fadi N Salloum; Vincent Florio; Jackie D Corbin; Sharron H Francis; Rakesh C Kukreja; Matthew A Movsesian
Journal:  J Pharmacol Exp Ther       Date:  2009-06-22       Impact factor: 4.030

8.  Sildenafil reduces alcohol-induced gastric damage: just say 'NO'.

Authors:  R Duffin; C A Shaw; A G Rossi
Journal:  Br J Pharmacol       Date:  2007-12-17       Impact factor: 8.739

9.  Functional Measurement of CYP2C9 and CYP3A4 Allelic Polymorphism on Sildenafil Metabolism.

Authors:  Peng-Fei Tang; Xiang Zheng; Xiao-Xia Hu; Cheng-Cheng Yang; Zhe Chen; Jian-Chang Qian; Jian-Ping Cai; Guo-Xin Hu
Journal:  Drug Des Devel Ther       Date:  2020-11-24       Impact factor: 4.162

10.  Gametogenesis in malaria parasites is mediated by the cGMP-dependent protein kinase.

Authors:  Louisa McRobert; Cathy J Taylor; Wensheng Deng; Quinton L Fivelman; Ross M Cummings; Spencer D Polley; Oliver Billker; David A Baker
Journal:  PLoS Biol       Date:  2008-06-03       Impact factor: 8.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.